For researching the Lean Bulk Stack:
LGD-4033 – For research use only, 1 filled oral syringe daily. LGD-4033 can be researched for up to 8 weeks. After completion of a cycle, there should be an 8-week break before resuming research.
RAD-140 – For research use only, 1 filled oral syringe daily. RAD-140 can be researched for up to 4 weeks.
MK-677 – For research use only, 1 filled oral syringe daily. MK-677 can be researched for up to 8 weeks.
MK-2866 – For research use only, 1 filled oral syringe daily. Ostarine can be researched for up to 8 weeks.
SR-9009 – For research purposes only, 1 filled oral syringe daily. SR9009 can be researched for up to 8 weeks. After a cycle, a 30-day break should be taken before resuming research.
PCT – For research purposes only, Nolva or Clomid can be used when the cycle is complete, at 1 oral syringe per day for 30 days.
LGD-4033
According to a clinical trial conducted at the Boston Medical Center’s Section of Endocrinology, Ligandrol can help improve lean body mass and muscle strength.
Another study conducted in January 2013 found that Ligandrol can help increase lean muscle mass, and was generally well tolerated by test subjects.
RAD-140
RAD140 is an investigational selective androgen receptor modulator (SARM) that is developed by Radius Health, Inc. for use in androgen replacement therapy. It was licensed to Ellipses Pharmaceuticals in 2020. Some of the potential benefits under investigation are for the treatment of conditions such as muscle wasting and bone loss.
RAD140 is an investigational selective androgen receptor modulator (SARM) that is developed by Radius Health, Inc. for use in androgen replacement therapy. It was licensed to Ellipses Pharmaceuticals in 2020. Some of the potential benefits under investigation are for the treatment of conditions such as muscle wasting and bone loss.
MK-677
Ibutamoren has been shown to sustain activation of the GH–IGF-1 axis and to increase lean body mass with no change in total fat mass or visceral fat. It is under investigation as a potential treatment for reduced levels of these hormones, such as in children or elderly adults with growth hormone deficiency, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising potential therapy for the treatment of frailty in the elderly. As of June 2017, ibutamoren is in the preclinical stage of development for growth hormone deficiency.
Ostarine
GTx Incorporated was founded in Memphis in 1997 and licensed rights to enobosarm from the University of Tennessee Research Foundation; the SARM compounds were invented by James T. Dalton, Duane D. Miller, Karen A. Veverka and their research teams at Ohio State University, the University of Tennessee and GTx, respectively.
By 2007, enobosarm was in a Phase II trial, and that year GTx signed an exclusive license agreement for its SARM program with Merck & Co. The companies ended the deal in 2010.
In August 2011, there was a double-blind, placebo controlled phase II trial that focused on elderly men and postmenopausal women which concluded that Enobosarm showed statistically significant improvements in total lean body mass and physical function without the negative side effects that are normally present with steroids
SR9009
SR9009, also known as Stenabolic, is a research drug that was developed by professor Thomas Burris of the Scripps Research Institute as an agonist of Rev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA) with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. In an animal study, some of its effects were found to be independent of REV-ERB with an unknown mechanism of action.
Activation of Rev-ErbA-α by SR9009 in mice increases exercise capacity by increasing mitochondria counts in skeletal muscle.
Abuse of SR9009 has been reported within the bodybuilding community, resulting in SR9009 being placed on the World Anti-Doping Agency list of prohibited drugs. SR9009 and the related SR9011 drug are described as “Hormone and Metabolic Modulators”.
